Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...
Sam Altman-backed Retro Biosciences is raising $1 billion to develop drugs that extend human lifespan by 10 years, the FT ...
Sam Altman, the CEO of OpenAI, has announced a shift in his previously critical perspective on President Donald Trump.
It comes following the online spat between Musk and OpenAI CEO Sam Altman over the Stargate artificial intelligence infrastructure project touted by the president earlier this week, who described ...
OpenAI CEO Sam Altman took the technology world by surprise on Thursday with the release of Operator, his company's first AI ...
OpenAI CEO Sam Altman will brief U.S. officials on super-agents—AI systems set to revolutionize software development, finance ...
With speculation online about OpenAI having reached the AGI stage of ChatGPT development, Sam Altman says that's not what's ...